Can a DNA Test Predict Your Risk from Radiation Therapy?

Dr. Joanne Weidhaas introduces PROSTOX—a cutting-edge test that uses microRNA biomarkers to predict a man’s individual risk of side effects from prostate cancer radiation therapy.

This simple DNA test can identify patients who may be more sensitive to radiation, helping guide important treatment decisions before therapy begins. ProstoX is designed to support shared decision-making and reduce the chance of long-term complications.

Dr. Weidhaas explains how the test works, what the results mean, and how it fits into modern prostate cancer care. She also answers audience questions and shares case examples showing how PROSTOX has helped patients avoid unnecessary harm.

🎥 Watch now: Advances in Prostate Cancer

Whether you’re considering radiation therapy or just want to stay informed, this is a must-see presentation on the future of personalized prostate cancer care.